3,5,3'-Triiodothyronine Sulfate As Thyromimetic Agent And Pharmaceutical Formulations Thereof
First Claim
Patent Images
1. A solid oral dosage composition comprising T3S as the active principle, in a quantity ranging from 1 to 1000 μ
- g further comprising;
a) a diluent consisting of;
an alkaline inorganic salt and microcrystalline cellulose;
b) a disintegrant selected in the group consisting of;
corn starch, croscarmellose or salts thereof, crospovidone or salts thereof, polymethacrylates and maltodextrin or salts thereof;
c) a glidant selected in the group consisting of;
glycerol dibehenate, tri-basic calcium phosphate, starch derivatives, talc, magnesium stearate and zinc stearate; and
d) a lubricant selected from the group consisting of;
silicates, including hydrate silicon dioxide, hydrate colloidal silica;
magnesium stearate;
zinc stearate; and
talc.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention regards the use of triiodothyronine sulfate, commonly named T3S, as a medicament having thyromimetic activity for the treatment of pathologies due to organic deficiency of triiodothyronine (T3), as such or in association with thyroxine (T4), and pharmaceutical formulations for oral administration thereof.
12 Citations
30 Claims
-
1. A solid oral dosage composition comprising T3S as the active principle, in a quantity ranging from 1 to 1000 μ
- g further comprising;
a) a diluent consisting of;
an alkaline inorganic salt and microcrystalline cellulose;b) a disintegrant selected in the group consisting of;
corn starch, croscarmellose or salts thereof, crospovidone or salts thereof, polymethacrylates and maltodextrin or salts thereof;c) a glidant selected in the group consisting of;
glycerol dibehenate, tri-basic calcium phosphate, starch derivatives, talc, magnesium stearate and zinc stearate; andd) a lubricant selected from the group consisting of;
silicates, including hydrate silicon dioxide, hydrate colloidal silica;
magnesium stearate;
zinc stearate; and
talc. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 22, 25, 26, 27, 28, 29, 30)
- g further comprising;
-
14-21. -21. (canceled)
- 23. A therapeutic or prophylactic treatment method for a hypothyroid condition due to total thyroid hormone depletion before 131I radiotherapy comprising administering a thyroidectomised patient T3S as the sole thyroid hormone replacement up to 5 days before radioactive isotope administration.
Specification